- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07270562
ORbitale Atherectomie voor Lesiepreparatie bij Patiënten met Chronische Ledemaatbedreigende Ischemie (ORACLE)
ORbitale Atherectomie voor Lesievoorbereiding bij Patiënten met Chronische Ledemaat-bedreigende Ischemie
ORACLE is a Europe-wide study that will follow 250 people with critical limb-threatening ischemia (CLTI). It aims to see how well orbital atherectomy (OA) works in real-life practice. OA is a procedure that uses a tiny spinning tool to gently remove hard calcium from inside an artery, helping to open the vessel so other treatments-like balloons or stents-can work better. The study focuses on people who have heavily calcified arteries in the femoropopliteal or infrapopliteal areas of the leg.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Claire Poulet, PhD
- Telefoonnummer: +41 79 385 16 78
- E-mail: oracue@cirse.org
Studie Contact Back-up
- Naam: Dhwani S. Korde, PhD
- Telefoonnummer: +4367762942469
- E-mail: oracue@cirse.org
Studie Locaties
-
-
-
Hull, Verenigd Koninkrijk, HU3 2JZ
- Werving
- Hull University Teaching Hospitals NHS Trust
-
Hoofdonderzoeker:
- Raghu Lakshminarayan, Dr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Adult CLTI patients with femoropopliteal or infrapopliteal calcified lesions treated with OA using the Stealth 360 Peripheral OA System for vessel preparation prior to any adjunctive endovascular procedure.
Beschrijving
Inclusion Criteria:
- Rutherford classification category ≥4;
- Treatment of femoropopliteal or infrapopliteal calcified lesions with OA using the Stealth 360 peripheral OA System;
- Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
- Patients competent and willing to provide informed consent.
Exclusion Criteria:
- Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
- Inadequate inflow (>30% stenosis) following optimization;
- Insufficient direct outflow (less than 1 run-off vessel);
- Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
- Patients planned to receive an above ankle amputation of the target limb;
- Patients enrolled in RESCUE (ClinicalTrials.gov ID NCT07270575).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Adult CLTI patients with femoropopliteal or infrapopliteal calcified lesions
Eligible patients are those who will undergo OA prior to any adjunctive endovascular procedure |
The Stealth 360™ Peripheral Orbital Atherectomy System uses a diamond-coated, eccentrically mounted crown with bi-directional capabilities that treat a wide range of vessels, enabling single device treatment of multiple lesions and vessel sizes.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of lesions with ≤30% residual stenosis after completion of full planned procedure
Tijdsspanne: Immediately after procedure completion
|
Defined as residual stenosis ≤30%, immediately after completion of full planned procedure (OA + any planned adjunctive intervention(s)). |
Immediately after procedure completion
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of lesions with ≤30% residual stenosis after any unplanned endovascular intervention(s)
Tijdsspanne: Immediately after procedure completion
|
Defined as residual stenosis ≤30% immediately after completion of additional unplanned endovascular intervention(s) (any endovascular procedure that was not part of the primary procedure plan). |
Immediately after procedure completion
|
|
Need for unplanned bailout stenting
Tijdsspanne: Immediately after procedure completion
|
Defined as any stent placement that was not part of the primary procedure plan. |
Immediately after procedure completion
|
|
Number of participants free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
Tijdsspanne: 12 and 24 months
|
Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
12 and 24 months
|
|
CD-TLR-free survival
Tijdsspanne: Until the end of the follow-up period of 2 years
|
Defined as time between first OA procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion. |
Until the end of the follow-up period of 2 years
|
|
Clinical response using Rutherford classification categories
Tijdsspanne: 12 and 24 months
|
The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss. |
12 and 24 months
|
|
Wound status
Tijdsspanne: 12 and 24 months
|
Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening). |
12 and 24 months
|
|
Freedom from amputation of the target limb
Tijdsspanne: 12 and 24 months
|
Defined as absence of any amputation of the target limb (above ankle). |
12 and 24 months
|
|
Amputation-free survival
Tijdsspanne: Until the end of the follow-up period of 2 years
|
Defined as time between first OA procedure and above-ankle amputation of the target limb. |
Until the end of the follow-up period of 2 years
|
|
Overall survival
Tijdsspanne: Until the end of the follow-up period of 2 years
|
Defined as the time between the first OA procedure and death of any cause. |
Until the end of the follow-up period of 2 years
|
|
Patient-reported health-related quality-of-life
Tijdsspanne: Baseline, 6, 12 and 24 months post treatment
|
Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD. |
Baseline, 6, 12 and 24 months post treatment
|
|
Frequency and severity of procedural complications and other adverse events
Tijdsspanne: Within 30 days after the OA procedure
|
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe. |
Within 30 days after the OA procedure
|
|
Clinical response using ankle-brachial index (ABI)
Tijdsspanne: 12 and 24 months
|
The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease. |
12 and 24 months
|
|
Clinical response using toe pressure
Tijdsspanne: 12 and 24 months
|
The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion. |
12 and 24 months
|
|
Clinical response using WIfi (wound, ischemia and foot infection) score
Tijdsspanne: 12 and 24 months
|
The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization. |
12 and 24 months
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie stoel: Gerd Grözinger, Prof. Dr. med., SLK Kliniken Heilbronn GmbH
- Studie stoel: Marianne Brodmann, Univ.-Prof. Dr. med., Medizinische Universität Graz
- Studie stoel: Stefan Müller-Hülsbeck, Prof. Dr. med., DIAKO Krankenhaus gGmBH
- Studie stoel: Raghu Lakshminarayan, Dr, Hull University Teaching Hospitals NHS Trust
Publicaties en nuttige links
Algemene publicaties
- Nordanstig J, Wann-Hansson C, Karlsson J, Lundstrom M, Pettersson M, Morgan MB. Vascular Quality of Life Questionnaire-6 facilitates health-related quality of life assessment in peripheral arterial disease. J Vasc Surg. 2014 Mar;59(3):700-7. doi: 10.1016/j.jvs.2013.08.099. Epub 2013 Dec 15.
- Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification System. Cardiovasc Intervent Radiol. 2017 Aug;40(8):1141-1146. doi: 10.1007/s00270-017-1703-4. Epub 2017 Jun 5.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Perifere slagaderziekte
- Oa
- CLTI
- Chronische ischemie van de ledematen
- Infrapopliteale slagaders
- Observationele cohortstudie
- Orbitale atherectomie
- Vaartuigvoorbereiding
- Gecalcificeerde perifere arteriële laesies
- Kritieke ledemaatbedreigende ischemie
- Femoropopliteale slagaders
- Atherectomie voor verkalkte laesies
Aanvullende relevante MeSH-voorwaarden
- Vaatziekten
- Hart-en vaatziekten
- Pathologische processen
- Chronische ziekte
- Ziekte attributen
- Atherosclerose
- Arteriosclerose
- Arteriële occlusieve ziekten
- Perifere vaataandoeningen
- Ischemie
- Pathologische aandoeningen, tekenen en symptomen
- Chronische ledemaatbedreigende ischemie
- Perifere arteriële ziekte
Andere studie-ID-nummers
- ORACLE
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .